Publications by authors named "Bagot M"
Cutaneous T-cell lymphoma (CTCL), characterized by malignant T-cell proliferation primarily in the skin, includes subtypes such as mycosis fungoides (MF) and Sézary syndrome (SS). The tumor microenvironment (TME) is central to their pathogenesis, with flow cytometry and histology being the gold standards for detecting malignant T cells within the TME. Alongside emerging molecular markers, particularly clonality analysis, these tools are indispensable for accurate diagnosis and treatment planning.
View Article and Find Full Text PDFPurpose: Mogamulizumab demonstrated improved outcomes vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.
Materials And Methods: This analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.
Results: A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab vorinostat arm.
Background: Mycosis fungoides (MF) is the most common form of cutaneous T cell lymphoma. While multiple guidelines provide treatment recommendations, there are currently no clear treatment algorithms for MF. Chlormethine gel is recommended by major treatment guidelines as a first-line option for stage IA-IIA disease, and, on the basis of these guidelines, used in combination with other therapies in patients with advanced-stage MF in clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- * Radiation oncologists must make tailored decisions for patient treatment, but these choices would benefit from more clinical evidence and research.
- * The article calls for a prospective trial to better understand how different radiation doses affect patient outcomes in primary cutaneous lymphoma treatment.
Approach to Mycosis Fungoides in children: Consensus-based recommendations.
J Am Acad Dermatol
December 2024
Article Synopsis
- This project gathered experts to create guidelines for treating a skin condition called pediatric Mycosis fungoides (MF), which is different from how adults are treated.
- They talked about important factors that go beyond just measuring the size of the disease, like itching, how it affects daily life, and feelings of worry or embarrassment.
- The team made 10 recommendations for managing both early and advanced stages of pediatric MF, but they still need more information on how to treat the later stages properly.
Psoriasis is an inflammatory skin disease characterized by epidermal and immune dysfunctions. Although efficient, current topical treatments display adverse effects, including skin atrophy and burning sensation, leading to poor patient adherence. To overcome these downsides, pickering emulsions were formulated in which the calcitriol-containing dispersed phase was stabilized with either cyclosporin A- or tacrolimus-loaded poly(lactic-co-glycolic) acid nanoparticles.
View Article and Find Full Text PDFArticle Synopsis
- Sezary syndrome (SS) used to have very few treatment options and not a good outlook for patients, but new therapies are helping a lot.
- In a study of 178 patients treated from 2012 to 2020, more advanced treatments led to much better survival rates: about 56% of patients lived at least 5 years.
- Patients who had a special treatment called allogeneic stem-cell transplantation (AlloSCT) had even better chances to survive, with around 91% living for 5 years, but those who couldn't get that treatment still faced challenges.
Article Synopsis
- Sézary syndrome is a rare and deadly skin cancer, and this study looked into the survival rates and factors affecting outcomes, particularly focusing on the treatment mogamulizumab.
- *The research analyzed data from 339 patients diagnosed between 2000 and 2020 across Europe, highlighting that age over 80 and large-cell transformation worsened survival rates.
- *Results indicated that patients treated with mogamulizumab had significantly lower mortality rates, suggesting it is an effective treatment option for Sézary syndrome.
Actinic keratosis: Current challenges and unanswered questions.
J Eur Acad Dermatol Venereol
July 2024
Article Synopsis
- - Actinic keratoses (AK) are skin lesions caused by prolonged sun exposure and can lead to skin cancer; current treatments aim to reduce AK and prevent cancer development.
- - The review covers the prevalence, risk factors, and effectiveness of treatments for AK, emphasizing the importance of addressing both visible and subclinical lesions due to the concept of 'field cancerization.'
- - Despite the availability of various treatment options, there is a lack of clear definitions and epidemiological data on AK, alongside limited public awareness which hinders early intervention and long-term cancer prevention strategies.
Cutaneous T-cell lymphomas (CTCL) are a diverse group of malignant blood disorders characterized by initial skin infiltration, and sometimes, tumor spreading to lymph nodes, blood, and viscera. Mycosis fungoides is the most common form. Sézary syndrome is a distinctive form of CTCL marked by a significant presence of circulating tumor cells in peripheral blood.
View Article and Find Full Text PDFHealing of complex wounds requires dressings that must, at least, not hinder and should ideally promote the activity of key healing cells, in particular fibroblasts. This in vitro study assessed the effects of three wound-dressings (a pure Ca alginate: Algostéril®, a Ca alginate + carboxymethylcellulose: Biatain alginate® and a polyacrylate impregnated with lipido-colloid matrix: UrgoClean®) on dermal fibroblast activity. The results showed the pure calcium alginate to be non-cytotoxic, whereas the other wound-dressings showed moderate to strong cytotoxicity.
View Article and Find Full Text PDFArticle Synopsis
- Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic skin cancers that require various treatment strategies; interferon-α (IFN-α) has been used for years, but only the pegylated form, PEG-IFN-α-2a, remains available, though not officially approved for these conditions.
- A study involving 105 patients across 10 countries assessed the effectiveness and safety of PEG-IFN-α-2a, focusing on the time to next treatment (TTNT) as a measure of its clinical benefit.
- Results showed a 53.3% overall response rate with better TTNT for patients receiving combination therapy (10.4 months) compared
Article Synopsis
- CD39 is an enzyme in a pathway that helps suppress the immune system and is linked to the growth and spread of solid tumors, particularly in skin-related cancers.
- Research found that CD39 is overexpressed in specific T-cell lymphomas, including Sezary syndrome and mycosis fungoides, in both blood and skin lymphocytes.
- The study suggests that blocking the CD39/CD73/adenosine pathway could be a promising approach for treating these types of cutaneous T-cell lymphomas.
The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis.
View Article and Find Full Text PDFThe term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis.
View Article and Find Full Text PDFMaintenance treatment can be recommended for patients with mycosis fungoides (MF) whose disease responds to primary treatment. While positive outcomes have been observed in small studies with maintenance therapy, there is a lack of practical guidelines and agreement on when and how maintenance therapy for MF should be approached. In this article, we discuss expert opinions and clinical experiences on the topic of maintenance therapy for patients with MF, with a focus on chlormethine gel.
View Article and Find Full Text PDFKimura disease (KD) is a rare, chronic angiolymphoproliferative inflammatory disease appearing to be mostly restricted to the skin and soft tissue. Cutaneous involvement of KD includes head and/or neck nodules showing suggestive histological features, frequently associated with an atopic dermatitis-like or prurigo-like presentation. KD is challenging to treat, with high rate of recurrence using current therapeutic strategies.
View Article and Find Full Text PDF(1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lymphoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes from the subpopulation with R/R MF. (2) Methods: This observational, retrospective, cohort study analyzed patient records (1984-2016) from 27 clinical sites in Europe.
View Article and Find Full Text PDF